The Intergroup Rhabdomyosarcoma Study-I. A final report.

  title={The Intergroup Rhabdomyosarcoma Study-I. A final report.},
  author={Harold M. Maurer and Mohan S Beltangady and Edmund A. Gehan and William M. Crist and Denman Hammond and Daniel M. Hays and Ruth Heyn and William W. Lawrence and William A Newton and J L Ortega},
  volume={61 2},
The results of treatment of 686, previously untreated patients younger than 21 years with rhabdomyosarcoma or undifferentiated sarcoma, who were entered on Intergroup Rhabdomyosarcoma Study-I (IRS-I) were analyzed after a minimum potential follow-up time of 7 years. Patients in Clinical Group I (localized disease, completely resected) were randomized to receive either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC + radiation. At 5 years, approximately 80% of patients given either… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 141 extracted citations

Head and neck sarcomas: epidemiology, pathology, and management.

Neurosurgery clinics of North America • 2013
View 3 Excerpts
Highly Influenced

Improved care of rhabdomyosarcoma in Jordan using less intensive therapy.

Pediatric blood & cancer • 2013
View 4 Excerpts
Highly Influenced

Rhabdomyosarcoma of the extremities in adults.

Acta orthopaedica Belgica • 2006
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…